Australia · Delayed Price · Currency is AUD Mesoblast Statistics
Total Valuation
Mesoblast has a market cap or net worth of AUD 3.13 billion. The enterprise value is 3.16 billion.
| Market Cap | 3.13B |
| Enterprise Value | 3.16B |
Important Dates
The last earnings date was Wednesday, August 26, 2026.
| Earnings Date | Aug 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Mesoblast has 1.30 billion shares outstanding. The number of shares has increased by 7.21% in one year.
| Current Share Class | 1.30B |
| Shares Outstanding | 1.30B |
| Shares Change (YoY) | +7.21% |
| Shares Change (QoQ) | +0.44% |
| Owned by Insiders (%) | 33.63% |
| Owned by Institutions (%) | 26.98% |
| Float | 844.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 18.00 |
| PB Ratio | 3.81 |
| P/TBV Ratio | 1,063.88 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 18.21 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.43, with a Debt / Equity ratio of 0.22.
| Current Ratio | 2.43 |
| Quick Ratio | 1.98 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.85 |
| Interest Coverage | -2.58 |
Financial Efficiency
Return on equity (ROE) is -9.86% and return on invested capital (ROIC) is -4.51%.
| Return on Equity (ROE) | -9.86% |
| Return on Assets (ROA) | -4.11% |
| Return on Invested Capital (ROIC) | -4.51% |
| Return on Capital Employed (ROCE) | -7.41% |
| Weighted Average Cost of Capital (WACC) | 8.91% |
| Revenue Per Employee | 1.61M |
| Profits Per Employee | -769,595 |
| Employee Count | 81 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 0.95 |
Taxes
In the past 12 months, Mesoblast has paid 886,092 in taxes.
| Income Tax | 886,092 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -1.20% in the last 52 weeks. The beta is 0.81, so Mesoblast's price volatility has been lower than the market average.
| Beta (5Y) | 0.81 |
| 52-Week Price Change | -1.20% |
| 50-Day Moving Average | 2.24 |
| 200-Day Moving Average | 2.31 |
| Relative Strength Index (RSI) | 58.41 |
| Average Volume (20 Days) | 2,508,419 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Mesoblast had revenue of AUD 173.82 million and -83.12 million in losses. Loss per share was -0.06.
| Revenue | 173.82M |
| Gross Profit | 139.09M |
| Operating Income | -74.08M |
| Pretax Income | -82.23M |
| Net Income | -83.12M |
| EBITDA | -65.05M |
| EBIT | -74.08M |
| Loss Per Share | -0.06 |
Balance Sheet
The company has 148.76 million in cash and 184.06 million in debt, with a net cash position of -35.30 million or -0.03 per share.
| Cash & Cash Equivalents | 148.76M |
| Total Debt | 184.06M |
| Net Cash | -35.30M |
| Net Cash Per Share | -0.03 |
| Equity (Book Value) | 821.63M |
| Book Value Per Share | 0.63 |
| Working Capital | 168.23M |
Cash Flow
In the last 12 months, operating cash flow was -63.36 million and capital expenditures -1.20 million, giving a free cash flow of -64.56 million.
| Operating Cash Flow | -63.36M |
| Capital Expenditures | -1.20M |
| Depreciation & Amortization | 8.68M |
| Net Borrowing | -8.25M |
| Free Cash Flow | -64.56M |
| FCF Per Share | -0.05 |
Margins
Gross margin is 80.02%, with operating and profit margins of -42.62% and -47.82%.
| Gross Margin | 80.02% |
| Operating Margin | -42.62% |
| Pretax Margin | -47.31% |
| Profit Margin | -47.82% |
| EBITDA Margin | -37.43% |
| EBIT Margin | -42.62% |
| FCF Margin | n/a |
Dividends & Yields
Mesoblast does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.21% |
| Shareholder Yield | -7.21% |
| Earnings Yield | -2.66% |
| FCF Yield | -2.06% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Mesoblast is 3.91, which is 58.94% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 3.91 |
| Price Target Difference | 58.94% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 93.24% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Mesoblast has an Altman Z-Score of 4.13 and a Piotroski F-Score of 4.
| Altman Z-Score | 4.13 |
| Piotroski F-Score | 4 |